Over 2000 drug entries from about 550 biotech companies in Phase 2, 3 or NDA development.
Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).
NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.
Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates.
Financial data are delayed 15-25 minutes.
Showing 587 companies
Company
Price
Change
No of Shares
Market Cap
Short Ratio
Updated
ABBV AbbVie Inc.
$86.98
+0.26 +0.30%
1.5 billion
$128.6 billion
8.84
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Depatuxizumab mafodotin ABT-414 | Glioblastoma (rGBM) | Phase 3 | Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019. |
Veliparib | Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) | Phase 3 | Phase 3 trial did not meet primary endpoints - April 19, 2017. |
Ibrutinib | Relapsed or refractory MCL mantle cell lymphoma | Approved | Approved November 13, 2013. |
Imbruvica | Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy | Approved | Approved February 12, 2014. |
Imbruvica | Deletion 17p | Approved | Approved July 19, 2014. |
VIEKIRA PAK | HCV - genotype 1 | Approved | Approved December 19, 2014. |
IMBRUVICA | Waldenström’s Macroglobulinemia | Approved | Approved January 29, 2015 - PCYC |
ABBV-8E12 | Alzheimer's disease | Phase 2 | Phase 2 initiation announced January 25, 2017. |
Venclexta (MURANO) | Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) | Approved | Approval announced June 11, 2018. |
Venetoclax - CANOVA | Relapsed or refractory multiple myeloma | Phase 3 | Phase 3 data due in 2021. |
Risankizumab | Psoriasis | Approved | FDA approval announced April 23, 2019. |
Imbruvica | Second-line Chronic graft-versus-host disease (GVHD) | Approved | Approval announced August 2, 2017. |
ABT-494 | Psoriatic Arthritis | Phase 3 | Phase 3 trial to commenced 2017. |
Rova-T (TRINITY) | Third-line Small Cell Lung Cancer | Phase 2 | Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507. |
Upadacitinib | Atopic Dermatitis | Phase 3 | Phase 3 trial met primary and secondary endpoints - October 31, 2019. |
Imbruvica | Marginal zone lymphoma | Approved | sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017. |
Glecaprevir/Pibrentasvir (G/P) | Hepatitis C virus (HCV) | Approved | Approval announced August 3, 2017. |
Elagolix | Uterine Fibroids | NDA Filing | NDA filing announced August 5, 2019. |
Elagolix | Endometriosis | Approved | FDA approval announced July 24, 2018. |
ABT-494 upadacitinib | Rheumatoid arthritis | Approved | FDA Approval announced August 16, 2019. |
Rova-T (TAHOE) | Second-line Small Cell Lung Cancer | Phase 3 | Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018. |
Rova-T (MERU) | First-line Small Cell Lung Cancer | Phase 3 | Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019. |
Imbruvica and Gazyva - iLLUMINATE | Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) | Approved | FDA approval announced January 28, 2019. |
IMBRUVICA (ibrutinib) | Waldenström’s Macroglobulinemia | Approved | FDA approval announced August 27, 2018. |
IMBRUVICA (ibrutinib) | Diffuse large B-cell lymphoma (DLBCL) | Phase 3 | Phase 3 trial did not meet primary endpoint - noted July 11, 2018. |
Venclexta | First line unfit AML | Approved | FDA approval announced November 21, 2018. |
Upadacitinib - U-ACHIEVE | Ulcerative colitis | Phase 2/3 | Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018. |
Venetoclax and obinutuzumab | Chronic Lymphocytic Leukemia | Phase 3 | FDA approval announced May 15, 2019. |
Ibrutinib (Imbruvica) | Pancreatic cancer | Phase 3 | Phase 3 primary endpoint not met (PFS/OS). |
Venclexta plus Gazyva | Chronic lymphocytic leukemia (CLL) | Phase 3 | Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%. |
Venclexta MIRROS | Acute myeloid leukemia (AML) | Phase 3 | Phase 3 data due 2H 2019. |
Venclexta BELLINI | Multiple myeloma | Phase 3 | Phase 3 primary endpoint met. |
Venetoclax and obinutuzumab | Chronic lymphocytic leukemia | sNDA Filing | sNDA filing announced June 4, 2019. |
Veliparib | Ovarian cancer | Phase 3 | Phase 3 presentation at ESMO 28 September 2019. |
Risankizumab ( LIMMITLESS ) | Psoriasis | Phase 3 | Phase 3 data presented at EADV October 10, 2019. |
IMBRUVICA (ibrutinib) and rituximab | Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). | sNDA Filing | sNDA filing announced November 8, 2019. |
$3.00
+0.24 +8.70%
51.2 million
$153.5 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
ABO-101 | Sanfilippo syndrome type B (MPS IIIB) | Phase 1/2 | Phase 1/2 interim data due 2H 2019. |
EB-101 | Recessive dystrophic epidermolysis bullosa (RDEB) | Phase 1/2 | Phase 3 trial initiation placed on clinical hold. |
ABO-102 | Sanfilippo syndrome type A (MPS IIIA) | Phase 1/2 | Phase 1/2 presentation at ESGCT October 25, 2019. |
ABO-202 | CLN1 disease (Infantile Batten disease) | Phase 1/2 | Phase 1/2 trial planned. Timing to be announced later in 2019. |
ABIO ARCA biopharma Inc.
$5.30
-0.12 -2.21%
1.6 million
$8.4 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Gencaro | Chronic Heart Failure | Phase 3 | Phase 3 trial to be initiated 1Q 2020 subject to financing. Interim data 4Q 2021; top-line data: 4Q 2022. |
$2.29
+0.07 +3.15%
56.9 million
$130.2 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
ARB-1467, tenofovir, and pegylated interferon | Hepatitis B (HBV) | Phase 2 | Phase 2 trial ongoing but no plans to continue further development. |
AB-452 | Hepatitis B | Phase 1 | Decision regarding clinical development due early 2020. |
AB-506 | Hepatitis B (HBV) | Phase 1 | Development to be discontinued - noted October 3, 2019. |
AB-729 | Hepatitis B (HBV) | Phase 1 | Phase 1a/b data due 1Q 2020. |
$51.40
+0.92 +1.82%
154 million
$7.9 billion
12/06/2019
$3.67
+0.09 +2.51%
10.1 million
$37 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
EDSIVO | Vascular Ehlers-Danlos Syndrome | CRL | CRL issued June 25, 2019. |
Tovaxin (Tcelna) | Secondary Progressive MS (SPMS) | Phase 2b | Phase 2b trial did not meet primary endpoint - October 28, 2016. |
ACER-001 | Urea cycle disorder (UCD) | Phase 2 | Pivotal bioavailability and bioequivalence trial Part A data due 4Q 2019; Part B due 1Q 2020 with NDA filing 1Q 2021. |
Osanetant | induced Vasomotor Symptoms (iVMS) | Phase 1/2 | Phase 1/2 trial to be initiated mid-2020. |
$6.17
+0.02 +0.33%
140.1 million
$864.4 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
ACH-4471 | C3 glomerulopathy (C3G) | Phase 2 | Phase 2 completion due 2020. |
JNJ-4178 | Hepatitis C (HCV) | Phase 2a | Janssen noted September 11, 2017 that no further development planned. |
Danicopan (ACH-4471) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 2 | Phase 2 presentation at ASH December 9, 2019 at 6pm ET. |
JNJ-4178 - OMEGA-1 | Hepatitis C (HCV) | Phase 2b | Janssen noted September 11, 2017 that no further development planned. |
ACH-5228 | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 1 | Phase 2 trial planned to commence 1H 2020. |
$0.91
-0.05 -5.20%
8.4 million
$7.6 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Cytisine | Smoking cessation | Phase 2b | Phase 2b data met primary endpoint in 3/4 arms - June 11, 2019. |
ACIU AC Immune SA
$8.78
+0.59 +7.20%
67.6 million
$593.2 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Crenezumab - CREAD 2 | Alzheimer’s disease | Phase 3 | Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met. |
RG6100 (Anti-Tau RO7105705) | Alzheimer’s disease | Phase 2 | Phase 2 data due 3Q 2020. |
ACI-24 (anti-Abeta vaccine) | Alzheimer's disease-like characteristics in individuals with Down syndrome | Phase 1/2 | Phase 1/2 interim data released July 2019. |
Crenezumab - CREAD 1 | Alzheimer’s disease | Phase 3 | Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met. |
ACI-24 | Alzheimer’s disease | Phase 2 | Phase 2 trial initiation announced August 20, 2018. |
MTAU9937A | Alzheimer’s disease | Phase 2 | Phase 2 trial initiation announced February 20, 2019. |
ACI-35 | Alzheimer’s disease | Phase 1b | Phase 2 trial planned for 1H 2019. |
ACI-3024 | Alzheimer’s disease | Phase 1 | Phase 1 trial initiation announced July 17, 2019. |
ACI-35.030 | Alzheimer’s Disease | Phase 1/2 | Phase 1b/2 trial initiation announced August 1, 2019. |
$1.71
+0.01 +0.59%
48 million
$82.1 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Ampyra | Improve walking in patients with multiple sclerosis | Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld. | |
CVT-427 | Migraine | Phase 1 | Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps. |
Tozadenant | Parkinson’s disease (PD) | Phase 3 | Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued. |
Dalfampridine | Post stroke deficits | Phase 3 | Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued. |
INBRIJA (CVT-301) | OFF episodes of Parkinson’s disease (PD) | Approved | FDA Approval announced December 22, 2018. |
BTT1023 | Primary Sclerosing Cholangitis | Phase 2 | Phase 2 interim data were slated for 3Q 2018 - no update given to date from company. |
$1.66
+0.04 +2.47%
41.4 million
$68.7 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
ATI-502 (ATI-50002-AA-201) - dose ranging | Alopecia areata | Phase 2 | Phase 2 data did not meet primary endpoint - June 26, 2019. |
ATI-502 (VITI-201 Topical) | Vitiligo | Phase 2 | Development to be discontinued - noted August 8, 2019. |
ATI-501 (AUAT-201 Oral) | Alopecia areata | Phase 2 | Phase 2 data met primary endpoint and some secondary endpoints - July 30, 2019. Partner required for further development. |
ESKATA (hydrogen peroxide) | Seborrheic keratosis (SK) | Approved | Approval announced December 15, 2017. |
A-101 THWART-1 and THWART-2 | Common warts (verruca vulgaris) | Phase 3 | Phase 3 data met all endpoints - September 16, 2019 and October 24, 2019. |
ATI-502 | Androgenetic alopecia (AGA) - Hair loss | Phase 2 | Partner required to further development. |
ATI-502 (AD-201 Topical) | Atopic dermatitis (AD) | Phase 2 | Phase 2 trial completed. |
ATI-450 | Rheumatoid arthritis (RA) | Phase 1/2 | Phase 1 data due 4Q 2019 or 1Q 2020. |
$1.87
+0.04 +2.19%
79.6 million
$148.8 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
ARX-04 (SAP302) | Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury | Phase 3 | Phase 3 data released August 15 2016 |
DSUVIA (ARX-04) | Moderate-to-severe acute pain following a surgical procedure | Approved | FDA Approval announced November 2, 2018. |
Zalviso | Post-operative pain following open abdominal surgery and hip or knee replacement surgery | Phase 3 | CRL Jul 26 2014. NDA resubmission timing to be known in 2H 2019. |
ACST Acasti Pharma Inc.
$1.86
-0.04 -2.11%
85.2 million
$158.7 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
CaPre (TRILOGY 1 and 2) | Hypertriglyceridemia | Phase 3 | Phase 3 top-line data due in December 2019 (1) and late-January 2020 (2). |
$1.12
-0.02 -1.75%
105.2 million
$117.8 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
MAGE-A4 (ADP-A2M4) | Soild tumors | Phase 1 | Phase 1 updated data at CTOS November 16, 2019 - ORR 7/14. |
AFP (ADP-A2AFP) | Hepatocellular carcinoma | Phase 1 | Phase 1 data update due 1H 2020. |
MAGE-A10 (ADP-A2M10) | Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Phase 1 further data due 2H 2019. |
MAGE-A4 (SPEARHEAD‑1) | Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) | Phase 2 | Phase 2 interim futility data due 1H 2020. |
MAGE-A4 (ADP-A2M4CD8 - SURPASS) | Soild tumors | Phase 1 | Phase 1 safety and response data due 1H 2020. |
$1.51
+0.13 +9.34%
10.3 million
$15.6 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AD04 | Alcohol use disorder | Phase 3 | Phase 3 trial due to commence December 2019 with data due in 2021. Data from second Phase 3 trial for U.S. required endpoint due 2023. |
ADMA ADMA Biologics Inc
$4.32
+0.19 +4.60%
59.3 million
$256.3 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
RI-002 | Primary Immune Deficiency Diseases | Approved | FDA Approval announced April 1, 2019. |
BIVIGAM | Primary humoral immunodeficiency | CRL | Response to Complete Response Letter submitted January 7, 2019. |
$0.55
+0.62%
61.6 million
$34.1 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Epinephrine Pre-filled Syringe (PFS) | Emergency treatment of anaphylaxis. | Approved | CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission. |
APC-1000 | Asthma/COPD | Phase 2 | Phase 3 development on hold - noted May 9, 2019. |
Symjepi - low dose | Anaphylaxis | Approved | FDA Approval announced September 27, 2018. |
Higher Dose Naloxone Injection | Opioid overdose | CRL | CRL announced November 25, 2019. |
APC-8000 (sublingual tadalafil) | Erectile dysfunction | NDA Filing | Refusal to file letter received February 26, 2019. |
$6.47
-0.04 -0.69%
27.9 million
$180.4 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
ADS-4101 | Partial onset seizures in patents with epilepsy | Phase 1b | Further development deferred - noted May 9, 2019. |
GOCOVRI (amantadine) | Multiple sclerosis (MS) | Phase 3 | Phase 3 data due 4Q 2019. |
Namzaric | Moderate to severe dementia of the Alzheimer's type. | Approved | Approved December, 24 2014. |
ADS-5102 | Levodopa-Induced Dyskinesia | Approved | Approval announced August 24, 2017. |
GOCOVRI (amantadine) | Dyskinesia patients with Parkinson's disease | Phase 3 | Phase 3 open-label data released April 19, 2018. |
ADRO Aduro Biotech Inc.
$1.15
-0.03 -2.54%
80.5 million
$92.6 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
ADU-S100 | Solid tumors or lymphomas | Phase 1b | Initial data at SITC November 2018 noted 2/40 PRs and 11 with SD. |
CRS-207 and GVAX Pancreas - ECLIPSE trial | Pancreatic cancer | Phase 2b | Phase 2b primary endpoint not met - May 2016 |
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial | Pancreatic cancer | Phase 2b | Partial clinical hold announced October 24, 2016. Hold released November 21, 2016. |
CRS-207 with pembrolizumab | Mesothelioma - cancer | Phase 2 | Noted December 12, 2017 that development to be discontinued. |
pLADD | Colorectal Cancer | Phase 1 | Phase 1 ongoing. |
pLADD | Colorectal Cancer | Phase 1 | Phase 1 ongoing. |
ADU-214 with Nivolumab | Non-Small Cell Lung Cancer | Phase 1/2 | Phase 1b initiation announced June 7, 2018. |
ADU-S100 and Spartalizumab | Solid tumors or lymphomas | Phase 1b | Phase 1 final data due 2020. |
ADU-S100 and ipilimumab | Melanoma | Phase 1 | Phase 1 commencement of dosing announced February 11, 2019. |
BION-1301 | IgA Nephropathy | Phase 1 | Phase 1 data due 2020. |
ADU-S100 and pembrolizumab | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 1/2 | Phase 1b/2 initiation of dosing announced September 4, 2019 with initial data due 2020. |
MK-5890 and pembrolizumab | Solid tumors | Phase 1 | Phase 1 data presented at SITC November 2019 noted one patient in each of the monotherapy and combo arms showed a partial response. |
$11.43
+0.89 +8.39%
64.6 million
$738.2 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
ADVM-043 | Alpha-1 Antitrypsin (A1AT) Deficiency | Phase 1/2 | Development to be discontinued - noted November 1, 2018. |
AVA-101 | Wet age-related macular degeneration (Wet-AMD) | Phase 2a | Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed. |
ADVM-022 | Wet age-related macular degeneration (Wet-AMD) | Phase 1 | Phase 1 third cohort to commence enrolment in 4Q 2019. Cohort 1 52-week data and Cohort 2 24-week data due 1H 2020. |
ADXS Advaxis Inc.
$0.77
+0.14 +21.75%
24.7 million
$19 million
12/06/2019
$19.86
+0.52 +2.66%
46.3 million
$920.2 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Roclatan | Glaucoma | Approved | FDA Approval announced March 12, 2019. |
Rhopressa | Glaucoma | Approved | PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017. |
AR-13503 | Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) | Phase 1/2 | Phase 1/2 trial initiation announced August 20, 2019. |
AR-1105 | Macular edema due to RVO (retinal vein occlusion) | Phase 2 | Phase 2 trial initiated March 2019. |
Roclatan - Mercury 3 | Open Angle Glaucoma | Phase 3 | Phase 3 top-line data due 1H 2020. |
AVX-012 | Dry eye disease | Phase 2b | Phase 2b trial to be initiated late-2020. |
$0.86
-0.01 -1.72%
20 million
$17.1 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Macimorelin Acetate - Macrilen | Adult Growth Deficiency | Approved | CRL issued November 2014. Approval announced following resubmission December 20, 2017. |
Zoptrex | Endometrial cancer | Phase 3 | Phase 3 trial did not meet primary endpoint - May 1, 2017. |
AFMD Affimed N.V.
$2.28
-0.03 -1.30%
76.2 million
$173.8 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AFM13 with Keytruda | Hodgkin Lymphoma - Cancer | Phase 1b | Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%. |
AFM13 | Hodgkin Lymphoma - Cancer | Phase 2 | Phase 2a ongoing. |
AFM13 | CD30-positive peripheral T cell lymphoma (PTCL) | Phase 2 | Phase 2 dosing has been initiated - noted November 19, 2019. |
AFM11 | Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) | Phase 1 | Phase 1 program terminated - noted May 22, 2019. |
AFM24 | EGFR-expressing solid tumors | Phase 1/2 | Phase 1/2a trial to commence 1Q 2020. |
AGEN Agenus Inc.
$3.91
-0.16 -3.93%
137.4 million
$537.1 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AGEN2034 and AGEN1884 | Solid tumors | Phase 1/2 | Phase 1/2 data due 2019. |
AGEN1884 (anti-CTLA-4) | Solid cancers | Phase 1 | Phase 1 data due 2019. |
Shingrix | Shingles | Approved | Approval announced October 20, 2017. |
AGEN2034 (anti-PD-1) | Cervical cancer | Phase 1/2 | Subset analysis of Phase I dose escalation trial presented at SITC November 8, 2019. |
AGEN1181 - 2nd gen CTLA | Advanced cancer | Phase 1 | Phase 1 data due 2019. |
$40.94
+0.86 +2.15%
68.4 million
$2.8 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AG-348 - Mitapivat | Thalassemia | Phase 2 | Phase 2 data due 4Q 2019. |
Ivosidenib | IDH1m Relapsed/Refractory AML - cancer | Approved | FDA Approval announced July 20, 2018. |
AG-348 (ACTIVATE) | Pyruvate kinase deficiency | Phase 3 | Phase 3 enrolment to be completed 2019. |
AG-120 and VIDAZA - AGILE | Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer | Phase 3 | Phase 3 enrolment to be completed 2020. |
Enasidenib (AG-221) - IDHENTIFY | Refractory Acute myeloid leukemia (AML) - cancer | Phase 3 | Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018. |
IDHIFA (enasidenib) - AG-221 | Advanced hematologic malignancies with an IDH2 mutation | Approved | Approval announced August 1, 2017. |
AG-120 Ivosidenib | IDH1 mutant positive cholangiocarcinoma - cancer | Phase 3 | sNDA filing due to be filed following final overall survival analysis mid-2020. |
AG-120 Ivosidenib | R/R Acute Myeloid Leukemia (AML) | Phase 1 | Phase 1 data at ASCO June 2018 noted CR rate was 24%. |
Enasidenib or ivosidenib with VIDAZA | Frontline AML with IDH1 or IDH2 mutation | Phase 1/2 | Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%. |
Ivosidenib or enasidenib | Frontline AML with IDH1 or IDH2 mutation | Phase 1 | Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%. |
AG-270 | Solid tumors | Phase 1 | Phase 1 data presented at AACR-NCI-EORTC October 27, 2019. Trial is ongoing. |
Vorasidenib (AG-881) | Glioma | Phase 3 | Phase 3 trial to be initiated YE 2019. |
Ivosidenib | Frontline AML with IDH1 mutation | Approved | FDA Approval announced May 2, 2019. |
Ivosidenib and Vorasidenib (AG-881) | IDHm low-grade glioma | Phase 1 | Phase 1 updated data noted 31% ORR with postoperative treatment - November 22, 2019. |
Ivosidenib | IDH1 mutant newly diagnosed AML ineligible for standard therapies | Phase 1 | Phase 1 updated data at ASCO June 3, 2019. 30% CR rate. |
Ivosidenib and azacitidine ( Vidaza) | Newly diagnosed AML with an IDH1 mutation | Phase 1 | Phase 1 updated data at ASH December 9, 2019 at 10:30 a.m. ET. |
AG-348 - Mitapivat (DRIVE) | Pyruvate Kinase Deficiency | Phase 2 | Phase 2 data to be presented at ASH December 9, 2019 from 6pm ET. |
$7.88
+0.14 +1.81%
29 million
$228.4 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AEB1102 | Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS) | Phase 1 | Phase 1 initiation announced July 2016. Enrollment to be completed in 2017. |
Pegzilarginase (AEB1102) | Arginase I deficiency | Phase 3 | Phase 3 trial initiation announced June 3, 2019 with data due 1Q 2021. |
AEB1102 | Solid tumors | Phase 1 | Phase 1 dose escalation data presented at AACR April 15, 2018. |
Pegzilarginase (AEB1102) | Solid tumors | Phase 1 | Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD. |
Pegzilarginase (AEB1102) + KEYTRUDA | Small cell lung cancer (SCLC) | Phase 2 | Phase 1/2 top-line data due 1H 2020. |
AEB4104 | Homocystinuria | Phase 1/2 | Phase 1/2 trial to be initiated 2Q 2020 with initial data due 1Q 2021. |
AGN Allergan plc
$186.37
+0.29 +0.16%
328.3 million
$61.2 billion
4.48
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Botox | Forehead lines | Approved | Approval (third indication) announced October 3, 2017. |
RTGel in combination with BOTOX | Overactive Bladder (OAB) | Phase 2 | Phase 2 trial to be completed 2H 2019. |
JUVÉDERM VOLLURE | Correction of moderate to severe facial wrinkles and folds | Approved | Approval announced March 20, 2017. |
Brazikumab | Crohn's disease | Phase 3 | Phase 3 ongoing. |
Botox | Depression | Phase 2 | Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned. |
RORγt agonist | Psoriasis | Phase 2b | Phase 2b trial ongoing. |
Cariprazine | Maintenance Treatment of Schizophrenia | Approved | Approval announced November 13, 2017. |
ABP 798 | RITUXAN biosimilar - non-Hodgkin lymphoma | BLA Filing | BLA filing due 1Q 2020. |
ATOGEPANT | Chronic migraine | Phase 3 | Phase 3 data due in 2020. |
RAPASTINEL | Major depressive disorder (MDD) | Phase 3 | Phase 3 trials did not meet primary endpoints - March 6, 2019. |
RELAMORELIN | Diabetic Gastroparesis | Phase 3 | Phase 3 top-line data due 2020. |
ESMYA (ulipristal acetate) | Uterine Fibroids | CRL | CRL issued August 21, 2018. |
ABICIPAR | Diabetic macular edema (DME) | Phase 3 | Phase 3 trial to be initiated 2019. |
Cenicriviroc (CVC) | Nonalcoholic steatohepatitis (NASH) | Phase 3 | Phase 3 data due 2020. |
ABICIPAR | Age-related macular degeneration (AMD) | PDUFA priority review | BLA acceptance of filing announced September 9, 2019. Estimated PDUFA date July 9, 2020. |
AVYCAZ (ceftazidime and avibactam) | Complicated Urinary Tract Infections (cUTI) | Approved | sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017. |
Oxymetazoline HCl cream 1.0% | Facial Erythema (Redness) Associated with Rosacea | Approved | Approved January 19, 2017. |
Linaclotide 72 mcg dose for use in the treatment of adults | Chronic idiopathic constipation (CIC) | Approved | sNDA approval announced January 26, 2017. |
MVASITM (bevacizumab-awwb) | Biosimilar candidate to Avastin (bevacizumab) | Approved | Approved September 14, 2017. |
Sarecycline | Severe acne vulgaris | Approved | FDA Approval announced October 2, 2018. |
Cariprazine | Bipolar I Depression | PDUFA | FDA Approval announced May 28, 2019. |
UBROGEPANT | Migraine | PDUFA | NDA acceptance announced March 11, 2019. PDUFA December 2019. No exact date provided. |
Brazikumab | Ulcerative colitis | Phase 2/3 | Phase 2/3 trial ongoing. |
Brimo DDS | Geographic atrophy | Phase 3 | Phase 3 trial to be initiated 2H 2018. |
Bimatoprost | Open-angle glaucoma or ocular hypertension | PDUFA | PDUFA date 1H 2020. No exact date announced. Estimate May 15, 2020. |
AVYCAZ (ceftazidime and avibactam) | Complicated Urinary Tract Infections (cUTI) - pediatric | Approved | FDA Approval announced March 18, 2019. |
Botox | Lower limb spasticity | Approved | FDA Approval announced October 24, 2019. |
Botox | Upper limb spasticity | Approved | FDA Approval announced June 21, 2019. |
AGN-241751 | Major Depressive Disorder (MDD) | Phase 2 | Phase 2 top-line data due 2H 2019. |
Presbysol | Presbyopia | Phase 3 | Phase 3 top-line data due 2020. |
RAPASTINEL | Depression | Phase 2 | Phase 2 monotherapy interim analysis 2H 2019. |
Juvéderm VOLUMA | Mid-Face Injection Via Cannula | Approved | FDA Approval announced September 3, 2019. |
$2.06
+0.03 +1.48%
59.3 million
$122.2 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Twirla | Contraceptive patch | PDUFA | CRLs issued 2013 and 2017. New PDUFA extended by three months to February 16, 2020. Advisory Committee Meeting October 30, 2019 voted 14 to 1 in favor. |
$2.87
-0.11 -3.69%
18.2 million
$52.3 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AAV Gene Therapy | Achromatopsia | Phase 1/2 | Phase 1/2 interim dose-escalation data due January 2020. |
rAAV-hRS1 | X-linked retinoschisis (XLRS) | Phase 1/2 | Phase 1/2 interim data released December 12, 2018. No signs of clinical activity. |
AAV-based gene therapy | X-linked Retinitis Pigmentosa (XLRP) | Phase 1/2 | Phase 1/2 dose expansion data due January 2020. |
$0.40
-0.01 -2.71%
8.3 million
$3.3 million
0.23
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Ampligen | CFS | CRL | CRL February 4, 2013. |
Ampligen, Intron A, celecoxib and pembrolizumab | Triple-Negative Breast Cancer | Phase 1 | Phase 1 data due around 2Q 2020. |
Ampligen, Intron A, and celecoxib | Colorectal cancer | Phase 2 | Phase 2 interim data due around 2Q 2020. |
Ampligen, cisplatin and pembrolizumab | Ovarian cancer | Phase 2 | Phase 2 interim data due around 4Q 2020. |
Ampligen, Intron A | Prostate Cancer | Phase 2 | Phase 2 trial to commence enrolment in 4Q 2019. |
Ampligen plus Intron A | Ovarian cancer | Phase 1/2 | Phase 1 interim data to be presented 1Q 2020. |
$29.65
+0.52 +1.79%
63.3 million
$1.9 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AR101 ARTEMIS | Peanut Allergy | Phase 3 | Phase 3 trial met primary endpoint - March 25, 2019. |
AR101 RAMSES | Peanut Allergy | Phase 3 | Phase 3 data released November 8, 2018 noted no serious adverse events |
AR101 | Peanut Allergy | PDUFA | PDUFA date late-January 2020. Advisory Committee meeting September 13, 2019 voted in favor of supporting approval. |
AR 201 | Egg Allergy | Phase 2 | Phase 2 trial to be completed 2H 2020. |
AR101 with adjunctive dupilumab | Peanut Allergy | Phase 2 | Phase 2 trial initiation announced October 15, 2018. |
AR101 POSEIDON | Peanut Allergy | Phase 3 | Phase 3 data due 2020. |
$5.91
-0.15 -2.48%
118.9 million
$703 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Vadadustat - TRILO2GY | Three-times-weekly dosing regimen for vadadustat | Phase 3 | Phase 3 trial to be initiated in 2019. |
Vadadustat - FO2RWARD | Renal anemia | Phase 2 | Phase 2 trial data due 2019. |
Auryxia | Hyperphosphatemia | Approved | Approved Sept 5, 2014. |
Vadadustat - INNO2VATE | Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) | Phase 3 | Phase 3 data due 2Q 2020. |
Vadadustat - PRO2TECT | Non-dialysis patients with anemia related to CKD (NDD-CKD) | Phase 3 | Phase 3 data due mid-2020. |
Auryxia | Iron deficiency anemia in non-dialysis dependent CKD patients | Approved | sNDA FDA Approval announced November 7, 2017. |
$17.64
+0.03 +0.17%
93.9 million
$1.7 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AKCEA-ANGPTL3-LRx | Rare hyperlipidemias | Phase 2 | Pilot study data due mid-2019. |
AKCEA-ANGPTL3-LRx | Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus | Phase 2b | Phase 2 data due early 2020. |
AKCEA-APOCIII-LRx | Hyperlipoproteinemia and established cardiovascular disease | Phase 2b | Phase 2b data due early 2020. |
AKCEA-APO(a)-LRx | Hyperlipoproteinemia(a) and established cardiovascular disease | Phase 2b | Phase 3 trial to be initiated 2H 2019. |
Inotersen (IONIS-TTRRx) | NEURO-TTR - familial amyloid polyneuropathy (FAP). | Approved | FDA Approval announced October 5, 2018, |
Volanesorsen - APPROACH | Familial chylomicronemia syndrome (FCS) | CRL | CRL issued August 27, 2018. |
Volanesorsen | Partial lipodystrophy rapidly | Phase 3 | Phase 3 initiated November 2015 |
Volanesorsen | Familial partial lipodystrophy (FPL) | Phase 3 | Phase 3 data met primary endpoint - August 6, 2019. |
AKCEA-TTR-LRx | hATTR Amyloidosis | Phase 3 | Phase 3 trial initiation announced November 25, 2019. |
$22.99
+0.93 +4.22%
28.6 million
$656.6 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AKR-001 | Nonalcoholic steatohepatitis (NASH) | Phase 2a | Phase 2a data due 1Q 2020. |
$1.98
+0.00%
21 million
$41.6 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Coversin - CAPSTONE | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 3 | Phase 3 staged readouts - no definitive timeline set by company. 2019? |
Coversin | Atopic keratoconjunctivitis | Phase 1/2 | Phase 1/2 Part B data due 4Q 2019. |
Coversin | Bullous Pemphigoid | Phase 2 | Phase 2 data presented at EADV Congress with a pivotal trial to commence 2H 2020. |
Coversin | Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) | Phase 3 | Phase 3 trial to commence by end of 2019. |
ALBO Albireo Pharma Inc.
$20.81
-0.59 -2.76%
12.7 million
$264 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Odevixibat (A4250) - PEDFIC- 1 | Progressive familial intrahepatic cholestasis (PFIC) | Phase 3 | Phase 3 top-line data due mid-2020. |
Elobixibat | Nonalcoholic steatohepatitis (NASH) | Phase 2 | Phase 2 data due mid-2020. |
Odevixibat (A4250) | Biliary atresia | Phase 3 | Phase 3 trial planned for 2020. |
$0.00
+0.00%
83.6 million
$
11/29/2019
Drug | Indication | Stage | News |
---|---|---|---|
Eptinezumab ALD403 | Frequent episodic migraine | PDUFA | PDUFA date February 21, 2020. |
ALD403 | Chronic Migraine | Phase 2b | Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016. |
ALD403 - PROMISE 1 | Frequent episodic migraine | Phase 3 | Phase 3 PROMISE 1 top-line data released June 27, 2017, Primary and key secondary endpoints met but competitive concerns raised. |
Eptinezumab | Acute migraine | Phase 3 | Phase 3 trial to be initiated 2H 2019. |
ALD1910 | Migraine | Phase 1 | Phase 1 commencement of dosing announced October 10, 2019. Initial data due 2H 2020. |
$4.73
-0.1 -1.97%
28 million
$132.2 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
ADX-102 - topical ocular reproxalap - RENEW | Dry eye syndrome | Phase 3 | Phase 3 (Part 1) data December 3, 2019 noted one co-primary endpoint was met while the other missed. Part 2 to be initiated 1H 2020. |
Reproxalap (ADX-102) - INVIGORATE | Allergic conjunctivitis | Phase 3 | Phase 3 trial to be initiated 1H 2020. |
ADX-102 reproxalap | Noninfectious anterior uveitis | Phase 3 | Phase 3 data did not meet endpoints - June 25, 2019. |
Reproxalap (ADX-102) | Sjögren-Larsson Syndrome (SLS) | Phase 3 | Phase 3 Part 1 section of trial completed. |
ADX-1612 (ganetespib) | Post-transplant lymphoproliferative disorder | Phase 2 | Phase 2 trial to be initiated 4Q 2019. |
ADX-2191 | Proliferative vitreoretinopathy (PVR) | Phase 3 | Phase 3 trial to be initiated 4Q 2019 with initial data due 2020. |
ALEC Alector Inc.
$19.76
+0.37 +1.91%
68.9 million
$1.4 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AL001 | Frontotemporal Dementia | Phase 1 | Phase 2 trial initiation announced September 9, 2019. |
AL002 | Alzheimer’s disease | Phase 1 | Phase 1 data presented at CTAD December 6, 2019 - generally safe and well-tolerated. |
AL003 | Alzheimer’s disease | Phase 1 | Phase 1 trial initiation announced April 3, 2019. |
$7.52
+0.75 +11.08%
5 million
$37.3 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Iluvien | Diabetic macular edema | Approved | CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014 |
ALKS Alkermes plc
$20.95
+0.3 +1.45%
157.5 million
$3.3 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD) | Schizophrenia | Approved | FDA approval announced July 2, 2018. |
ALKS 3831 - ENLIGHTEN-2 | Schizophrenia, bipolar | NDA Filing | NDA filing announced November 19, 2019. |
BYDUREON | Type 2 diabetes | Approved | CRL received March 15, 2010. |
Aristada | Schizophrenia | Approved | Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017. |
Diroximel fumarate (BIIB098) | Multiple sclerosis (MS) | Approved | FDA Approval announced October 30, 2019. |
ALKS 6428 | Opioid dependence | Phase 3 | Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing. |
ALKS 5461 | Major depressive disorder | CRL | CRL announced February 1, 2019. |
ALKS 3831 - ENLIGHTEN-1 | Schizophrenia | Phase 3 | Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain. |
ALKS 4230 ARTISTRY-1 | Solid tumors | Phase 1 | Phase 1/2 data at SITC November 2019 - 8/14 SD for monotherapy, 12/18 for combo (incl. 2 PRs). |
Aristada and Invega Sustenna | Schizophrenia | Phase 3 | Phase 3 data released April 9, 2019 - primary endpoint met. |
ALKS 4230 + Keytruda - ARTISTRY-2 | Solid tumors | Phase 1 | Phase 1 data presented at SITC November 8, 2019. |
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera - | Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 3 | Phase 3 top-line data met primary endpoint - July 30, 2019. |
ALKS 4230 + Keytruda (ION-01) | Head and neck squamous cell cancer | Phase 2 | Phase 2 trial to be initiated 4Q 2019. |
ALLK Allakos Inc.
$117.36
-5.7 -4.63%
48.7 million
$5.7 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AK002 | Severe Allergic Conjunctivitis | Phase 1 | Phase 1 data May 7, 2019 noted a 78% median improvement in ocular symptoms |
AK002 | Indolent Systemic Mastocytosis | Phase 1 | Phase 1 data released February 19, 2019. |
AK002 | Chronic Urticaria | Phase 2 | Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate. |
AK002 | Eosinophilic Gastritis | Phase 2 | Phase 2 top-line data met primary and secondary endpoints - August 5, 2019. Extension data due 1H 2020. Phase 3 trial to commence 1Q 2020. |
$31.40
+1.86 +6.30%
121.9 million
$3.8 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
UCART19 (PALL) | Acute lymphoblastic leukemia (ALL) | Phase 1 | Phase 2 trial to be initiated in 2020. |
UCART19 - CALM | Refractory B-cell Acute Lymphoblastic Leukaemia | Phase 1 | Phase 1 trial ongoing. |
ALLO-715 | Multiple myeloma | Phase 1/2 | Phase 1/2 trial initiated 3Q 2019. |
ALLO-501 - ALPHA | Non-Hodgkin lymphoma (NHL) | Phase 1 | Phase 1 initial data due 1H 2020. |
$1.91
-0.04 -2.05%
23.5 million
$44.8 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Reloxaliase ALLN-177 (URIROX-1) | Enteric Hyperoxaluria | Phase 3 | Phase 3 trial met primary endpoint, key secondary endpoint missed - November 7, 2019. |
Reloxaliase ALLN-177 (Study 206) | Primary hyperoxaluria | Phase 2 | Phase 2 presentation at ASN November 8, 2019. |
Reloxaliase ALLN-177 (URIROX-2) | Enteric Hyperoxaluria | Phase 3 | Phase 3 data due 2H 2021. Noted December 4, 2019 that it intends to discuss with the FDA a proposal to reduce target enrolment and conduct an earlier interim analysis. |
$123.76
-0.47 -0.38%
111.5 million
$13.8 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Givosiran | Acute hepatic porphyrias | Approved | FDA approval announced November 20, 2019. |
Inclisiran - ORION-9 | Hypercholesterolemia | Phase 3 | Phase 3 data met all endpoints - September 25, 2019. Data November 18, 2019 noted LDL-C reductions of 50%. |
ALN-HBV02 (VIR-2218) | Chronic hepatitis B virus (HBV) | Phase 1/2 | Phase 1/2 additional data due 1H 2020. |
Lumasiran (ALN-GO1) ILLUMINATE-A | Primary Hyperoxaluria Type 1 (PH1) | Phase 3 | Phase 3 data due late-2019. |
Patisiran | Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR | Approved | FDA Approval announced August 10, 2018. |
ALN-CC5 (cemdisiran) | IgA nephropathy | Phase 2 | Phase 2 trial ongoing. |
Fitusiran (ATLAS) | Hemophilia | Phase 3 | Phase 3 ongoing. |
ALN-TTRsc02 - HELIOS-A | ATTR amyloidosis | Phase 3 | Phase 3 trial enrolling - noted December 6, 2018. |
Inclisiran - ORION-10 | Cardiovascular disease (ASCVD) | Phase 3 | Phase 3 data met all endpoints - September 25, 2019. Detailed data due at AHA noted 58% LDL-C lowering. |
Inclisiran - ORION 11 | Cardiovascular disease (ASCVD) | Phase 3 | Phase 3 trial met all primary and secondary efficacy endpoints. Noted September 2, 2019 a 54% LDL-C lowering after 11 months and 50% over 18 months. |
ALN-AAT02 | alpha-1 anti-trypsin deficiency-associated liver disease | Phase 1/2 | Phase 1/2 data due late-2019. |
Lumasiran (ALN-GO1) ILLUMINATE-B | Primary Hyperoxaluria Type 1 | Phase 3 | Phase 3 top-line data due mid-2020. |
Patisiran APOLLO-B | Wild-type ATTR amyloidosis patients with cardiomyopathy | Phase 3 | Phase 3 enrolment to be completed late-2020. |
Lumasiran (ALN-GO1) ILLUMINATE-C | Impaired renal function | Phase 3 | Phase 3 trial data due end of 2020. |
ALN-AGT | Hypertension | Phase 1 | Phase 1 trial ongoing. |
ALN-TTRsc02 (vutrisiran) - HELIOS-B | ATTR amyloidosis with cardiomyopathy | Phase 3 | Phase 3 trial has been initiated - noted November 22, 2019. |
$3.07
+0.1 +3.37%
18.6 million
$57.1 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
N91115 | Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein | Phase 2 | Phase 2 data released February 24, 2017 - primary endpoint not met. |
ALPN-101 | Healthy volunteers | Phase 1 | Phase 1 presentation at ASH December 8, 2019: 11:00 AM ET. |
ALPN-202 | Advanced Malignancies | Phase 1 | Phase 1 trial to be initiated 1Q 2020. |
$0.50
+0.02 +3.38%
27.8 million
$13.8 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
ALRN-6924 | Peripheral T-cell lymphoma (PTCL) | Phase 2a | Noted that development to be discontinued - no pivotal trial. |
ALRN-6924 and Cytarabine (Ara-C) | Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS) | Phase 1b | Phase 1/1b trial ongoing. |
ALRN-6924 and IBRANCE (palbociclib) | Solid tumors | Phase 2a | Phase 2a final data due 2Q 2020. |
ALRN-6924 and Paclitaxel | Breast cancer | Phase 1 | Phase 1 has been initiated. |
ALRN-6924 | Small Cell Lung Cancer (SCLC) | Phase 1/2 | Phase 1b/2 dose-optimization data due 2Q 2020. |
ALT Altimmune Inc.
$1.88
+0.05 +2.73%
15.3 million
$28.8 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
HepTCell | Hepatitis B | Phase 1 | Phase 2 trial planned for 2020. |
NasoVAX | Flu vaccine | Phase 2 | Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected. |
NASOSHIELD | Anthrax | Phase 1b | Phase 1b trial to be initiated in 1Q 2020. |
ALT-801 | Non-alcoholic steatohepatitis (NASH) | Phase 1 | IND to be filed in 2020 with Phase 1 data due 2021. |
$113.89
+6.47 +6.02%
221.3 million
$25.2 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
CAEL‐101 | AL amyloidosis | Phase 2/3 | Phase 2b/3 trial to be initiated 1H 2020 with data due in 2021. |
ACH-4471 | C3 glomerulopathy (C3G) | Phase 2 | Phase 2 completion due 2020. |
Eculizumab | Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) | Approved | FDA Approval announced June 27, 2019. |
ULTOMIRIS (ravulizumab-cwvz) | atypical Hemolytic Uremic Syndrome (aHUS) | Approved | FDA Approval announced October 18, 2019. |
ULTOMIRIS (ravulizumab-cwvz) | Paroxysmal nocturnal hemoglobinuria (PNH) | Approved | FDA approval announced December 21, 2018. |
Eculizumab | Refractory generalized myasthenia gravis (gMG) | Approved | Approval announced October 23, 2017. |
Danicopan (ACH-4471) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 2 | Phase 2 presentation at ASH December 9, 2019 at 6pm ET. |
ACH-5228 | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 1 | Phase 2 trial planned to commence 1H 2020. |
ALXN1840 (WTX101) | Wilson disease | Phase 3 | Phase 3 top-line data due 1H 2021. |
ULTOMIRIS (ravulizumab-cwvz) | Generalized myasthenia gravis (gMG) | Phase 3 | Phase 3 trial initiated 1Q 2019. |
ALXN1830 | Warm autoimmune hemolytic anemia (WAIHA) | Phase 1/2 | Phase 2/3 trial to be initiated early 2020. |
ULTOMIRIS (ravulizumab-cwvz) subcutaneous | Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) | Phase 3 | Phase 3 PK data due 1H 2020. |
Elamipretide | Leber’s hereditary optic neuropathy (LHON) | Phase 2 | Phase 2 trial did not meet primary endpoint. Phase 3 trial planned for 2020. |
Elamipretide | Primary mitochondrial myopathy | Phase 3 | Phase 3 data due January 2020. |
ULTOMIRIS | Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) | Phase 3 | Phase 3 trial to commence 1H 2020. |
Eculizumab | Generalized myasthenia gravis (gMG) - children | Phase 3 | Phase 3 trial has commenced - noted October 23, 2019. |
Eculizumab | Neuromyelitis Optica Spectrum Disorder (NMOSD) - children | Phase 3 | Phase 3 trial to commence by the end of 2019. |
$11.07
+0.36 +3.36%
33.9 million
$375.4 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
AMAG-423 / Digoxin immune fab (DIF) | Severe preeclampsia in pregnant women | Phase 2/3 | Phase 2/3 top-line data due 1H 2020. |
Vyleesi (Bremelanotide) | Female sexual dysfunction (FSD) | Approved | FDA approval announced June 21, 2019. |
Feraheme | Adults with iron deficiency anemia (IDA) | Approved | Approval for sNDA filing announced February 5, 2018. |
Makena - auto injector | Reduce the risk of preterm birth in women with a singleton pregnancy | Approved | Approval announced February 14, 2018. |
Makena | Preterm birth | Phase 3 | Advisory Committee voted 9-7 recommending withdrawal from market - October 29, 2019. |
Ciraparantag | Anticoagulated reversal agent / Healthy volunteers | Phase 2 | End of Phase 2 trial meeting slated for 2H 2020. |
AMGN Amgen Inc.
$233.77
+0.36 +0.15%
594.2 million
$138.9 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Tezepelumab - NAVIGATOR | Asthma | Phase 3 | Phase 3 data due late-2020. |
Prolia (denosumab) | Glucocorticoid-induced osteoporosis (GIOP) | Approved | Approval announced May 21, 2018. |
KYPROLIS (ASPIRE) | Relapsed Multiple Myeloma | Approved | sNDA approval announced June 11, 2018. |
Vectibix (Panitumumab) | Wild-Type RAS Metastatic Colorectal Cancer | Approved | sBLA approval announced June 29, 2017. |
MVASITM (bevacizumab-awwb) | Biosimilar candidate to Avastin (bevacizumab) | PDUFA | Approved September 14, 2017. |
Corlanor | Chronic Heart Failure | Approved | Approved April 15, 2015. |
Erenumab | Migraine | Approved | Approval announced May 17, 2018. |
CNP 520 | Alzheimer’s Disease | Phase 3 | Phase 3 ongoing. Expected completion 2024. |
OTEZLA | Scalp Psoriasis | sNDA Filing | sNDA filing pending. |
OTEZLA - PSA-006 | Psoriatic Arthritis | Phase 3 | Phase 3 - primary endpoint met. |
OTEZLA | Behçet’s Disease | Approved | FDA Approval announced July 19, 2019. |
Repatha | Cardiovascular disease | Approved | Approval announced December 1, 2017. |
XGEVA | Multiple Myeloma | Approved | sBLA approval announced January 5, 2017. |
KYPROLIS (ARROW) | Multiple Myeloma | Approved | FDA approval announced October 1, 2018. |
KYPROLIS (ENDEAVOR) | Relapsed Multiple Myeloma | Approved | sNDA approved January 17, 2018. |
BLINCYTO | Ph+ R/R ALL | Approved | PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017. |
ABP 798 | RITUXAN biosimilar - non-Hodgkin lymphoma | BLA Filing | BLA filing due 1Q 2020. |
ABP 980 (Kanjinti; trastuzumab-anns) | Herceptin biosimilar | CRL | FDA approval announced June 13, 2019. |
ABP 710 | REMICADE biosimilar - rheumatoid arthritis | Approved | FDA Approval announced December 6, 2019. |
Parsabiv | Secondary hyperparathyroidism (SHPT) | Approved | Approved February 7, 2017. |
EVENITY (Romosozumab) | Osteoporosis | Approved | FDA Approval announced April 9, 2019. |
Omecamtiv mecarbil GALACTIC-HF | Acute heart failure | Phase 3 | Phase 3 interim analysis 1H 2020. |
Omecamtiv mecarbil METEORIC-HF | Acute heart failure | Phase 3 | Second Phase 3 trial initiation announced February 21, 2019. Enrolment to continue through 2020. |
AMG 420 | Relapsed. Refractory (R/R) Multiple Myeloma (MM) | Phase 1 | Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts. |
AMG 330 | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | Phase 1 | Phase 1 data at ASH December 1, 2018 noted 12.5% ORR. |
Nplate (Romiplostim) | Immune Thrombocytopenia (Pediatric) | Approved | FDA approval announced December 14, 2018. |
Nplate (Romiplostim) | Immune thrombocytopenia (ITP) | Approved | FDA Approval announced October 18, 2019. |
KYPROLIS (CANDOR) | Multiple Myeloma | Phase 3 | Phase 3 data met primary endpoint - September 13, 2019. LBA at ASH December 10, 2019, 7:30 AM. |
OTEZLA - ADVANCE | Plaque psoriasis | Phase 3 | Phase 3 trial is initiating. |
AMG 594 | Healthy volunteers | Phase 1 | Phase 1 trial initiation announced February 20, 2019. |
AMG 510 | Solid tumors | Phase 1 | Phase 1 update at ESMO noted 54% PR rate for NSCLC patients (960mg); 1/12 for CRC patients. Next update due in 2020. |
CNP520 | Alzheimer’s Disease | Phase 2/3 | Phase 2/3 trial discontinued due to lack of efficacy. |
BLINCYTO | Acute lymphoblastic leukemia (ALL) - pediatric | Phase 3 | Phase 3 enrolment terminated due to treatment benefit over chemo. Primary endpoint of event-free survival met. |
AMG 570 | Systemic Lupus Erythematosus (SLE) | Phase 2 | Phase 2 trial is enrolling. |
Tezepelumab | Chronic obstructive pulmonary disease (COPD) | Phase 2 | Phase 2 trial is enrolling. |
$0.42
-0.01 -1.98%
158.6 million
$66.6 million
16.03
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Ampion | Osteoarthritis of the Knee | Phase 3 | As of July 24, 2019 enrolment has reached approximately 30%. |
Optina | Diabetic Macula Edema | Phase 2b | Phase 2b data released May 2015 did not meet endpoints |
$18.92
-0.11 -0.58%
46.9 million
$888.1 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Albuterol DPI | Asthma | Phase 2b | |
Naloxone Intranasal | Opioid overdose | CRL | CRL announced February 21, 2017. |
Primatene Mist (epinephrine inhalation aerosol) | Asthma | CRL | CRL issued December 27, 2016. |
$22.45
+0.64 +2.93%
358.9 million
$8.1 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Vascepa | High Triglycerides With Mixed Dyslipidemia | PDUFA priority review | PDUFA date December 28, 2019. Advisory Committee meeting November 14, 2019 voted 16-0 in favor. |
$3.68
-0.03 -0.81%
299.1 million
$1.1 billion
3.86
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
IPX203 | Parkinson's disease | Phase 3 | Phase 3 data due 1H 2020. |
K127 | Myasthenia Gravis | NDA Filing | NDA filing planned. |
ANAB AnaptysBio Inc.
$14.02
-0.21 -1.48%
27.1 million
$380.4 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
ANB020 - etokimab | Moderate-to-severe adult atopic dermatitis | Phase 2b | Phase 2b data failed to meet primary endpoint - November 8, 2019. |
ANB020 - etokimab | Severe adult eosinophilic asthma | Phase 2a | Phase 2b trial initiation postponed. |
ANB019 | Palmo-plantar pustular psoriasis | Phase 2 | Phase 2 data due 1H 2020. |
ANB019 | Generalized pustular psoriasis | Phase 2 | Phase 2 interim data on first TWO patients announced September 30, 2019 with patients reaching primary endpoint. Further data due 2020. |
ANB020 - etokimab | Nasal polyps | Phase 2 | Phase 2 data due 1Q 2020. |
$1.59
-0.02 -1.30%
7.4 million
$11.8 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Inodiftagene - Codex | Non-muscle invasive bladder cancer (NMIBC) | Phase 2 | Phase 2 trial discontinued due to lack of efficacy - November 15, 2019. |
Inodiftagene with BCG - Leo | Non-muscle invasive bladder cancer (NMIBC) | Phase 3 | Phase 3 planned for 4Q 2019 or 1Q 2020. |
$57.48
+0.43 +0.75%
14.3 million
$820.2 million
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
Cingal | Osteoarthritis | Phase 3 | Phase 3 trial did not meet primary endpoint - June 19, 2018. Further trial to be initiated 1H 2020. |
Monovisc | Osteoarthritis | Approved | Approved Feb 2014 |
HYALOFAST | Cartilage defects of the knee | Phase 3 | Phase 3 enrollment to be completed by the end of 2018. |
$3.74
-0.03 -0.80%
20.2 million
$75.6 million
12/06/2019
$23.99
-1.86 -7.20%
63.9 million
$1.5 billion
12/06/2019
Drug | Indication | Stage | News |
---|---|---|---|
APL-2 subcutaneous | Cold agglutinin disease (CAD) | Phase 2 |